Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07198087 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
A Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL), sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT07198087: Recruiting Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL), sponsored by Ono Pharmaceutical Co..
NCT07198087 is a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL) that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 32 participants, below the 177-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07198087, a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL), is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
Conditions Studied
Interventions
- DRUG Tirabrutinib
Study Locations (2)
Florida
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center, Inc. - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT07198087 shows while recruiting
NCT07198087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 177-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Primary Central Nervous System Lymphoma (PCNSL) appearing as the primary indexed condition, and to 1 intervention - of which Tirabrutinib is the first listed.
NCT07198087 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07198087 about?
NCT07198087 is a clinical study titled "A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants". A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
What is the current status of trial NCT07198087?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-10-01. Estimated completion is 2026-12-31.
What conditions does trial NCT07198087 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma (PCNSL).
What interventions are being tested in trial NCT07198087?
The interventions under investigation include: Tirabrutinib (DRUG).
Who is sponsoring clinical trial NCT07198087?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07198087 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma (PCNSL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
COMPLETED · Phase 1
-
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI